---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-249951"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2026-06-01T12:51:21+00:00"
generated_at: "2026-06-01T12:55:18.677080+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Edgewise sells sevasemten to Servier for $1.55B upfront, plus up to $1.1B milestones

## Summary
- $1.55B upfront cash; potential $1.1B in regulatory and commercial milestones totaling up to $2.65B.
- Edgewise to focus on cardiovascular pipeline (EDG-7500, EDG-15400, EDG-003).
- Upfront proceeds fully fund EDG-7500 development through potential approval.
- On track to report 12-week CIRRUS-HCM Part D data in Q2 2026.
- Transaction expected to close Q3 2026, subject to HSR and customary conditions.

## SEC filing metadata
- accession: 0001193125-26-249951
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2026-06-01T12:51:21+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000119312526249951/0001193125-26-249951-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000119312526249951/d24037d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-249951
- JSON: https://secwatch.observer/filing/0001193125-26-249951.json
- Plain text: https://secwatch.observer/filing/0001193125-26-249951.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.